Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

940 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ; CANTOS Trial Group. Ridker PM, et al. Among authors: libby p. Lancet. 2017 Oct 21;390(10105):1833-1842. doi: 10.1016/S0140-6736(17)32247-X. Epub 2017 Aug 27. Lancet. 2017. PMID: 28855077 Clinical Trial.
Cystatin C deficiency in human atherosclerosis and aortic aneurysms.
Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, Ridker PM, Libby P, Chapman HA. Shi GP, et al. Among authors: libby p. J Clin Invest. 1999 Nov;104(9):1191-7. doi: 10.1172/JCI7709. J Clin Invest. 1999. PMID: 10545518 Free PMC article.
Soluble CD40L and cardiovascular risk in women.
Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Schönbeck U, et al. Among authors: libby p. Circulation. 2001 Nov 6;104(19):2266-8. doi: 10.1161/hc4401.099447. Circulation. 2001. PMID: 11696462
Inflammation and atherosclerosis.
Libby P, Ridker PM, Maseri A. Libby P, et al. Circulation. 2002 Mar 5;105(9):1135-43. doi: 10.1161/hc0902.104353. Circulation. 2002. PMID: 11877368 Review.
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.
Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. Naghavi M, et al. Among authors: libby p. Circulation. 2003 Oct 14;108(15):1772-8. doi: 10.1161/01.CIR.0000087481.55887.C9. Circulation. 2003. PMID: 14557340 Review.
940 results